IPO registrations (S-1, F-1) · Registrants

Vyant Bio, Inc.

SEC CIK
1349929 · filings on EDGAR ↗
Former names
CANCER GENETICS, INC (2011–2021); CANCER GENETICS INC (2006–2010)
Registration
Form S-1, first filed 2011-12-30, last 2022-04-29; 5 initial registrations, 27 amendments
Outcome
Final prospectus filed 2013-04-05; declared effective 2013-04-04; withdrawal requested 2013-03-29
Industry (SIC)
Services-Medical Laboratories 8071
Incorporated in
DE
Business address
2370 STATE ROUTE 70 WEST, SUITE 310, Cherry Hill,, NJ 08002
EIN
04-3462475
EDGAR entity type
operating
Insiders and CEO pay
Vyant Bio, Inc. on the corporate pages

Offering terms

Proposed price range
$10.00–$12.00 per share (S-1/A filed 2013-04-01)
Final price
$10.00 per share, within the range (424B4 filed 2013-04-05, an initial public offering)
Shares sold
600,000
Gross proceeds
$6,000,000 before underwriting discounts and any over-allotment option
Listing
under the symbol CGIX
Lead underwriters
Aegis Capital (420,000 shares)
Syndicate
Feltl and Company (180,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 54

FiledFormWhat it isName as filedEDGAR
2011-12-30S-1S-1 (registration)CANCER GENETICS, INC0001193125-11-356362 ↗
2012-02-14S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-059565 ↗
2012-03-13S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-112311 ↗
2012-04-03S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-146686 ↗
2012-04-23S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-175594 ↗
2012-04-30S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-196735 ↗
2012-05-07S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-213736 ↗
2012-05-16S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-235838 ↗
2012-10-23S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-430558 ↗
2012-11-16S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-472809 ↗
2012-12-14S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-12-502167 ↗
2013-01-08S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-006376 ↗
2013-01-23S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-019562 ↗
2013-02-08S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-046270 ↗
2013-02-12S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-050021 ↗
2013-02-12S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-051961 ↗
2013-02-14S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-055860 ↗
2013-03-04S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-088936 ↗
2013-03-11S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-100617 ↗
2013-03-22S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-119990 ↗
2013-03-29RWRW (withdrawal request)CANCER GENETICS, INC0001193125-13-134761 ↗
2013-04-01S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-136969 ↗
2013-04-04EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-13-000878 ↗
2013-04-05424B4424B4 (final prospectus)CANCER GENETICS, INC0001193125-13-144246 ↗
2013-06-05S-1S-1 (registration)CANCER GENETICS, INC0001193125-13-248745 ↗
2013-07-12S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-289434 ↗
2013-07-25S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-301581 ↗
2013-08-05S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-318295 ↗
2013-08-12S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-330064 ↗
2013-08-13EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-13-002396 ↗
2013-08-14424B4424B4 (final prospectus)CANCER GENETICS, INC0001193125-13-334651 ↗
2013-10-08S-1S-1 (registration)CANCER GENETICS, INC0001193125-13-394340 ↗
2013-10-17S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-401850 ↗
2013-10-21S-1/AS-1/A (amendment)CANCER GENETICS, INC0001193125-13-404751 ↗
2013-10-22EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-13-003045 ↗
2013-10-23424B4424B4 (final prospectus)CANCER GENETICS, INC0001193125-13-408121 ↗
2014-06-05EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-14-001688 ↗
2016-12-22S-1S-1 (registration)CANCER GENETICS, INC0001349929-16-000139 ↗
2017-01-11S-1/AS-1/A (amendment)CANCER GENETICS, INC0001349929-17-000004 ↗
2017-01-13EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-17-000106 ↗
2017-06-05EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-17-001456 ↗
2020-07-21EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-20-001874 ↗
2021-02-08EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-21-000510 ↗
2021-02-12EFFECTEFFECT (declared effective)CANCER GENETICS, INC9999999995-21-000629 ↗
2021-06-04EFFECTEFFECT (declared effective)Vyant Bio, Inc.9999999995-21-002212 ↗
2022-04-29S-1S-1 (registration)Vyant Bio, Inc.0001493152-22-011626 ↗
2022-05-09EFFECTEFFECT (declared effective)Vyant Bio, Inc.9999999995-22-001377 ↗
2022-05-12424B4424B4 (final prospectus)Vyant Bio, Inc.0001493152-22-012936 ↗
2023-03-27EFFECTEFFECT (declared effective)Vyant Bio, Inc.9999999995-23-000666 ↗
2023-03-27EFFECTEFFECT (declared effective)Vyant Bio, Inc.9999999995-23-000667 ↗
2023-03-27EFFECTEFFECT (declared effective)Vyant Bio, Inc.9999999995-23-000669 ↗
2023-03-27EFFECTEFFECT (declared effective)Vyant Bio, Inc.9999999995-23-000670 ↗
2023-03-27EFFECTEFFECT (declared effective)Vyant Bio, Inc.9999999995-23-000671 ↗
2023-03-27EFFECTEFFECT (declared effective)Vyant Bio, Inc.9999999995-23-000675 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2013-04-01S-1/Aregistration statement$10.00–$12.00$11.00600,000$6,600,000 CGIX2primary document; range, price sentence, shares headline, proceeds computed, cover names 2document ↗
2013-04-05424B4final prospectus$10.00600,000$6,000,000 CGIX2primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 2document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Cannon EdmundDirector102013–2019
Chaganti Raju S.K.Director122013–2019
CZEREPAK ELIZABETHOfficerChief Financial Officer12013
El Naggar Jane HouldsworthOfficerVP of Research and Development32013–2014
PAPPAJOHN JOHNDirector; Director,TenPercentOwner352013–2019
Pecora Andrew LDirector42013
PRENDERGAST FRANKLYN GDirector92013–2019
SHARMA PANNADirector,OfficerChief Executive Officer; President & CEO72013–2017
Thompson Tommy GDirector22013
Brownlie Keith LDirector42013–2014
Rothman PaulDirector22014
Sitar Edward JOfficerCFO, Secretary & Treasurer; Chief Financial Officer72014–2016
Welsh Michael J.Director72014–2017
Harris Geoffrey E.Director192014–2023
McLeod HowardDirector102014–2022
Hepburn StevenOfficer; OtherVP of Biopharma Marketing42015
Shaknovich RitaOfficerChief Medical Officer; VP of Hematopathology Services32015–2018
ROBERTS JOHN ADirector,Officer; OfficerChief Executive Officer; Chief Operating Officer132016–2022
Gitelman IgorOfficerChief Accounting Officer32017
Brandt RalfOfficerPresident, Discovery Services42017–2021
Widmann Thomas FDirector12017
McCartney Michael BrianOfficerChief Commercial Officer22018
Miles Michael GlennOfficerChief Financial Officer32018–2020
Finger William LansingOfficerEVP Precision Medicine12019
Boehm MarcusDirector132021–2022
FLETCHER R JOHNDirector102021–2023
Hansen Paul R.Director112021–2023
Horobin JoannaDirector82021–2023
LaFrence Andrew D.C.OfficerChief Financial Officer72021–2022
Yeh Yung-PingDirector; Director,OfficerChief Innovation Officer72021–2022
Fremeau Robert Thomas Jr.OfficerChief Scientific Officer32021–2022

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2021-02-03CANCER GENETICS, INCBiotechnology$10,000,000$10,000,00061
2017-03-27CANCER GENETICS, INCBiotechnology$6,000,000$6,000,00031
2016-12-05CANCER GENETICS, INCBiotechnology$5,500,000$5,500,000161
2016-05-25CANCER GENETICS, INCBiotechnology$5,000,000$5,000,000411

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationCANCER GENETICS, INC.NJState business registriesEIN (EXACT, as the state registration reports it)
Plan sponsorVYANT BIO, INC.MNForm 5500 (employee benefit plans)EIN (EXACT)
Form D issuerCANCER GENETICS, INCNJForm D private offeringsCIK (EXACT)
SEC filerVyant Bio, Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerVYANT BIO, INC.NJTrademarks (USPTO)name and state
Form 5500 plan sponsorVYANT BIO, INC.EIN (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Services-Medical Laboratories, NJ first:

More with this interest.

In other datasets, the same topic (Health) in NJ:

Interests: Services-Medical Laboratories · Health